Metabolic Syndrome Following Transplant for Leukemia

描述（由申请人提供）：儿童期急性白血病的成年幸存者具有比预期更高的肥胖频率，心血管疾病的早期死亡率，以及代谢综合征（MS）的风险增加，并且这在接受造血细胞移植（HCT）作为其治疗的一部分的个体中可能更常见。本研究的主要目的是评估HCT特异性治疗暴露与胰岛素抵抗发展之间的关系，以及青少年和年轻成人HCT治疗儿童恶性血液病后幸存者的MS，该应用是Baker博士最近K23奖的成功进展的结果，该奖项被资助研究HCT后幸存者的晚期效应。该提案的具体目标是：1）测量胰岛素抵抗（IR，正葡萄糖胰岛素钳夹）血清胰岛素、葡萄糖和脂质;获得血压和人体测量结果;以及在190名HCT幸存者和190名对照中进行DEXA扫描; 2）评估特定HCT治疗暴露与MS发展的关联; 3）测量细胞因子、CRP和脂肪因子; 4）测量内皮功能受损和亚临床心血管疾病的早期体征;和5）获得HCT幸存者和对照者的饮食摄入和体力活动的测量。这些数据将说明以下假设：a）HCT存活者IR将更多，并且随着HCT后随访时间的延长，IR将独立于年龄增加，B）特异性HCT治疗暴露将与生长激素缺乏和更高程度的IR相关，c）同种异体HCT将与更高水平的与IR相关的炎症介质相关，d）亚临床心血管变化的血管测量在MS幸存者中将更高，并且将与全身照射暴露（TBI）相关，e）HCT存活者将较少进行体力活动，这将与暴露于TBI和患有移植物抗宿主病相关。这项研究提供了一个重要而令人兴奋的机会，探索儿童癌症治疗的潜在可改变的晚期效应，MS以及相关的过早心血管疾病和2型糖尿病的风险增加。由于HCT是广泛应用于白血病以及儿童和成人中许多其他恶性和非恶性疾病的治疗方式，每年全球有数千人成为幸存者，因此它是一个越来越重要的研究群体。

DESCRIPTION (provided by applicant): Adult survivors of acute leukemia in childhood have a higher than expected frequency of obesity early mortality from cardiovascular disease, and an increased risk for the metabolic syndrome (MS), and this may be more common in individuals who received hematopoietic cell transplant (HCT) as part of their therapy. The major objective of this research is to evaluate the relationship between HCT specific treatment exposures and the development of insulin resistance and the MS in adolescent and young adult survivors after HCT for treatment of hematologic malignancies in childhood, and this application is the result of the successful progression of Dr. Baker's recent K23 award, funded to study late effects in survivors after HCT. The specific aims of this proposal are: 1) to measure insulin resistance (IR, euglycemic insulin clamp) serum insulin, glucose, and lipids; to obtain blood pressure, and anthropometric measurements; and DEXA scans in 190 survivors of HCT and 190 controls; 2) evaluate the association of specific HCT treatments exposures with the development of the MS; 3) to measure cytokines, CRP and adipokines; 4) to measure early signs of impaired endothelial function and sub-clinical cardiovascular disease; and 5) to obtain measures of dietary intake and physical activity in HCT survivors and controls. These data will address the hypotheses that a) HCT survivors will be more IR, and that IR will increase independent of age with longer follow-up after HCT, b) specific HCT treatment exposures will be associated with growth hormone deficiency and higher degrees of IR, c) allogeneic HCT will be associated with higher levels of inflammatory mediators associated with IR, d) vascular measurements of sub-clinical cardiovascular changes will be higher in survivors with MS and will be associated with total body irradiation exposure (TBI), e) HCT survivors will be less physically active and this will be correlated with exposure to TBI and with having had graft vs. host disease. This research offers a significant and exciting opportunity to explore a potentially modifiable late effect of childhood cancer treatment, the MS and the associated heightened risk for premature cardiovascular disease and type 2 diabetes. Since HCT is a widely applied therapeutic modality for leukemia as well as many other malignant and non-malignant diseases in children and adults with thousands of individuals worldwide every year becoming survivors, it is an increasingly important group to study.